Bladder Cancer Treatment and Recurrence Algorithmic Tests

I.   The use of bladder cancer treatment and recurrence algorithmic tests is considered **medically necessary** when:

    A. The member has a diagnosis of bladder cancer, **AND**

    B. The results of algorithmic testing will affect management decisions for the member's bladder cancer, **AND**

    C. The member has <u>not</u> previously undergone bladder cancer treatment and recurrence algorithmic testing for the current cancer diagnosis.

II. The use of bladder cancer treatment and recurrence algorithmic test is considered **investigational** for all other indications.

REFERENCES

1. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. "MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer" (L38576). Available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38576